Association between liver fibrosis and C-peptide in patients with type 2 diabetes and nonalcoholic fatty liver disease
DOI:10.3969/j.issn.1001-5256.2021.05.030
- VernacularTitle:血清C肽在2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化进展中的作用
- Author:
Jiao LIU
1
;
Caiqin REN
;
Yali FENG
;
Jirui HE
Author Information
1. Department of Geriatrics, The Second Hospital of Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Diabetes Mellitus, Type 2;
Non-alcoholic Fatty Liver Disease;
C-Peptide
- From:
Journal of Clinical Hepatology
2021;37(5):1132-1136.
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect of serum C-peptide level on the progression of liver fibrosis in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). MethodsA total of 484 patients with T2DM who were admitted to Department of Geriatrics, The Second Hospital of Lanzhou University, from December 2018 to July 2020 were enrolled, and according to the results of abdominal ultrasound examination, they were divided into simple T2DM group with 107 patients and T2DM+NAFLD group with 377 patients. According to NAFLD fibrosis score, the patients with T2DM and NAFLD were divided into fibrosis exclusion subgroup （T2DM+F0） with 136 patients, uncertain subgroup (T2DM+F1) with 146 patients, and fibrosis subgroup (T2DM+F2) with 95 patients. Medical history data and laboratory markers were collected. The chi-square test was used for comparison of categorical data; the t-test or the Mann-Whitney U test was used for comparison of continuous data, and a one-way analysis of variance or the Kruskal-Wallis H test was used for comparison between multiple groups; a logistic regression analysis was used to explore the risk factors for the progression of liver fibrosis; the receiver operating characteristic (ROC) curve was used to analyze the clinical value of serum C-peptide in predicting and diagnosing the progression of liver fibrosis. ResultsCompared with the simple T2DM group, the T2DM+NAFLD group had a significant increase in C-peptide level (Z=-6.040,P＜0.001); compared with the T2DM+F1 and T2DM+F0, the T2DM+F2 had significantly higher C-peptide level ［2.89 (1.84-3.77) vs 1.97 (1.12-2.65)/1.87 (1.25-2.68), H=36.023,P＜0.001) and rate of fasting C-peptide (56.84% vs 23.29%/24.27%, χ2=37.583,P＜0001). The logistic regression analysis showed that C-peptide (OR=1.435, 95% confidence interval: 1.227~1.678， P＜0.001) was a risk factor for liver fibrosis in patients with T2DM and NAFLD, and the ROC curve analysis also showed that C-peptide had great significance in predicting liver fibrosis in such patients, with an area under the ROC curve of 0.814, a sensitivity of 642%, a specificity of 897%, and a Youden index of 0.539 at the optimal cut-off value of 2.405 ng/ml. ConclusionC-peptide is an independent risk factor for the progression of liver fibrosis in patients with T2DM and NAFLD.
